XNAS
OCEAW
Market cap1mUSD
Jun 11, Last price
0.01USD
Name
Ocean Biomedical Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-3m
L
CFO
-4m
L-55.67%
Profile
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 3,798 | |||||
Unusual Expense (Income) | ||||||
NOPBT | (3,798) | |||||
NOPBT Margin | ||||||
Operating Taxes | (1,524) | |||||
Tax Rate | ||||||
NOPAT | (3,798) | 1,524 | ||||
Net income | (3,301) | 565 -100.91% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (48,514) | |||||
BB yield | ||||||
| Debt | ||||||
Debt current | 16,300 | 12,118 | 2,150 | |||
Long-term debt | ||||||
Deferred revenue | 3,150 | |||||
Other long-term liabilities | 64,629 | 66,252 | ||||
Net debt | 16,300 | 8,722 | (108,622) | |||
| Cash flow | ||||||
Cash from operating activities | (4,180) | (9,429) | (747) | |||
CAPEX | ||||||
Cash from investing activities | (2,100) | |||||
Cash from financing activities | 3,400 | 10,399 | 2,100 | |||
FCF | (2,806) | 14,939 | (3,837) | |||
| Balance | ||||||
Cash | 4 | 328 | ||||
Long term investments | 3,392 | 110,443 | ||||
Excess cash | 3,396 | 110,772 | ||||
Stockholders' equity | (205,535) | (196,055) | 107,678 | |||
Invested Capital | 188,848 | 183,662 | 1,920 | |||
ROIC | ||||||
ROCE | 22.76% | |||||
| EV | ||||||
Common stock shares outstanding | 27,503 | 13,225 | ||||
Price | 0.55 -16.21% | 0.66 -93.65% | 10.40 4.10% | |||
Market cap | 15,209 | 137,540 4.10% | ||||
EV | 31,509 | 28,918 | ||||
EBITDA | (3,798) | |||||
EV/EBITDA | ||||||
Interest | 2,046 | 691 | ||||
Interest/NOPBT | ||||||